What is the risk reduction associated with adding ezetimibe to statins for patients with diabetes?
Hong et al. (2018) included seven trials (n=28,191 [7,298 with DM]) comparing a statin plus ezetimibe versus a statin alone or placebo and stratified by the presence of DM. The addition of ezetimibe to statins in patients with DM was associated with a greater reduction in CV events compared to those respectively. Zhan et al. (2018) found that ezetimibe added to statins reduced CV event risk versus a statin alone (RR: 0.94, 95% CI: 0.9 0.98).